Clinical trial
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954 is registered in ClinicalTrials.gov with argenx as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
- Lead sponsor
- argenx
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 20, 2024
- Completion date
- November 30, 2026
- Enrollment
- 3 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.